NCT01490879已完成2 期
A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon® in the Treatment of Subjects With a Diabetic Foot Ulcer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 168
- 试验地点
- 25
- 主要终点
- Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment
研究概览
简要总结
This study is for Type I or Type II diabetic subjects with with a diabetic foot ulcer. The study is being done to determine if Nexagon® plus standard of care is more effective than placebo plus standard of care. Standard of care will include debridement of the ulcer, standardized dressings and standardized off-loading using a Removable Cast Walker.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of diabetes mellitus (Type I or II)
- •HbA1c of less than or equal to 12.0%
- •Diagnosis of neuropathic foot ulcer with partial or complete neuropathy
- •Cutaneous ulcer on the plantar or dorsal aspect of the foot or toe that is greater or equal to 1.0cm2 and less than or equal to 8.0 cm2 in area at the end of the screening period and is full thickness with no exposed ligament, tendon, joint capsule or bone. Surface area will be measured by digital planimetry.
- •The Medical Monitor(or delegate)must confirm that the reference diabetic foot ulcer (RDFU)is suitable for inclusion after reviewing digital photographs
- •Wound bed consisting of completely viable tissue or one where completely viable tissue will be achieved by the end of the screening period.
- •An Ankle Branchial Index (ABI) of greater or equal to 0.80 in concert with a bi- or tri-phasic Doppler flow pattern; or adequate circulation as demonstrated by any of the following methods: peri-wound transcutaneous partial pressure oxygen (TcpO2)greater or equal to 40 mmHg; or a toe pressure of greater or equal to 40 mmHg; or skin perfusion pressure of greater or equal to 40 mmHg.
- •Ulcer present for 4 weeks or more or less than or equal to 12 months.
- •Willing to wear a Removable Cast Walker (RCW) between study visits for the duration of the study.
- •Signed informed consent form.
排除标准
- •Any unstable medical condition that would cause the study to be detrimental to the subject.
- •Decrease in RDFU size by more than 40% or increase in the ulcer size by more than 40% during the 14-day screening period as measured by digital planimetry.
- •Ulcers caused primarily by untreated vascular insufficiency or ulcers with an etiology not related to diabetes.
- •Ulcers above the ankle.
- •Ulcers that cannot be effectively off-loaded using the cast walker and sole insert provided in this study (ulcers not located on the weight bearing surface of the foot do not require off-loading).
- •Ulcers on the toes not accessible for photography (e.g. in the web space).
- •Presence of other ulcers within 2cm of the perimeter of the RDFU.
- •Cannot tolerate or will not comply with the off-loading method, or non-compliance with standard or care.
- •10.The RDFU is infected (clinical assessment of infection)and/or biopsy proof of greater than 100,000 organisms per gram of tissue during the screening period.
- •Subjects presenting with the clinical characteristics of cellulitis at the ulcer site.
- •Necrosis, purulence, or sinus tracts that cannot be removed by debridement.
- •Definite or suspected osteomyelitis within any wound located anywhere on the subjects body.
- •Acute Charcot's neuroarthropathy as determined by clinical and/or previous radiographic examination.
- •Severe Charcot deformity or rocker bottom foot with an associated plantar mid-foot or heel ulcer.
- •Revascularization surgery on the leg with the wound to be treated less than or equal to 4 weeks prior to the start of the screening period.
- •Requirement for concurrent topical antimicrobials to treat the RDFU after the end of the screening period.
- •Received dermal substitute or living skin equivalent (e.g. Dermagraft® or Apligraf®) within 14 days prior of the start of the screening period.
- •Severe complications of diabetes that in the opinion of the Investigator could interfere with wound healing or impede the subject's participation.
- •Subjects on concurrent immunosuppressive therapy to include oral corticosteroid therapy equivalent to greater than 5 mg/day of prednisone.
- •Any history of radiation therapy to the foot.
- •Female subjects who are pregnant or lactating.
- •Pre-menopausal women not using effective birth control methods as determined by the Investigator.
- •Life expectancy of < 12 months.
- •Subjects on renal replacement therapy.
- •Cancer within the last 3 years except basal and squamous cell carcinoma.
- •Cancer within the RDFU
研究组 & 干预措施
Nexagon® High Dose
Experimental
Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
干预措施: Nexagon® High Dose (Drug)
Nexagon® Low Dose
Experimental
Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
干预措施: Nexagon® Low Dose (Drug)
Nexagon® Medium Dose
Experimental
Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
干预措施: Nexagon® Medium Dose (Drug)
Nexagon® vehicle
Placebo Comparator
Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
干预措施: Nexagon® vehicle (Drug)
结局指标
主要结局
Incidence of Reference Diabetic Foot Ulcer (RDFU) complete closure determined by Investigator Assessment
时间窗: Within 12 weeks
次要结局
- Percentage change in RDFU surface area(Within 12 weeks)
- Time to RDFU complete closure(Within 12 weeks)
- Percentage of granulation tissue in RDFU(12 weeks)
- Incidence of ulcer recurrence(12 weeks post-closure)
- Incidence of adverse events(12 weeks)
研究者
研究点 (25)
Loading locations...
相似试验
终止
不适用
Clinical Trial Evaluating the Safety and Efficacy of the Use of Chitosan Gel in Patients With Chronic WoundsDiabetic Foot UlcerNCT04178525Primex ehf46
撤回
1 期
Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) PatientsDiabetic Foot UlcersNCT02367690Karyopharm Therapeutics Inc
已完成
不适用
High Purity Type I Collagen Based Skin Substitute Vs Dehydrated Human Amnion/Chorion Membrane in Treatment of DFUsDiabetic Foot Ulcer (DFU)NCT06470087Adichunchanagiri Institute of Medical Sciences, B G Nagara28
已完成
3 期
Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot UlcersDiabetic Foot UlcerNCT01181453Organogenesis314
已完成
1 期
Treatment of Diabetic Foot Ulcers With AUP1602-CDiabetic Foot UlcerNCT04281992Aurealis Oy26